About E3 ubiquitin-protein ligase NHLRC1
E3 ubiquitin-protein ligase NHLRC1 (NHLRC1) is a protein
from Homo sapiens identified by UniProt accession
Q6VVB1, 395 residues long.
MolForge cross-references it against 0 known binders and
135 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase NHLRC1 |
| UniProt accession | Q6VVB1 |
| Gene | NHLRC1 |
| Organism | Homo sapiens |
| Length | 395 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (135)
Diseases linked to this target (Open Targets).
- Lafora disease · score 0.78
- myoclonic epilepsy of Lafora 2 · score 0.75
- genetic disorder · score 0.47
- myoclonic epilepsy of Lafora 1 · score 0.40
- disorder of glycogen metabolism · score 0.37
- thiopurine metabolite measurement · score 0.35
- thiopurine methyltransferase activity measurement · score 0.33
- myelosuppression · score 0.31
- Seizure · score 0.11
- endometrial cancer · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6VVB1-F1 | alphafold | PREDICTED | 85.42 | — |
Amino-acid sequence (395 residues)
MAAEASESGP ALHELMREAE ISLLECKVCF EKFGHRQQRR PRNLSCGHVV CLACVAALAH PRTLALECPF CRRACRGCDT SDCLPVLHLI ELLGSALRQS PAAHRAAPSA PGALTCHHTF GGWGTLVNPT GLALCPKTGR VVVVHDGRRR VKIFDSGGGC AHQFGEKGDA AQDIRYPVDV TITNDCHVVV TDAGDRSIKV FDFFGQIKLV IGGQFSLPWG VETTPQNGIV VTDAEAGSLH LLDVDFAEGV LRRTERLQAH LCNPRGVAVS WLTGAIAVLE HPLALGTGVC STRVKVFSSS MQLVGQVDTF GLSLYFPSKI TASAVTFDHQ GNVIVADTSG PAILCLGKPE EFPVPKPMVT HGLSHPVALT FTKENSLLVL DTASHSIKVY KVDWG
Explore E3 ubiquitin-protein ligase NHLRC1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets